The $50 Medicare GLP-1 Deal: Do You Qualify?

Starting July 1, 2026, Medicare Part D beneficiaries can get GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge program. For men over 65 with obesity — and there are millions — this is the single biggest access expansion since GLP-1s launched. Here's who qualifies, what's covered, and what's not.

What the Program Covers

The Medicare Bridge program covers three specific GLP-1 medications at a $50/month copay: Wegovy (semaglutide injection), Zepbound KwikPen (tirzepatide injection), and Foundayo (the newest approved GLP-1 for obesity). The copay is fixed at $50 regardless of the drug's list price — the government covers the difference directly, not through Part D insurers.

This is not a discount card or a manufacturer coupon. It's a government-funded program that bypasses the traditional Part D coverage structure. The $50 copay applies throughout the coverage year — no donut hole, no catastrophic phase adjustments.

Who Qualifies

You need to meet all of the following:

Medicare Part D enrollment. You must be enrolled in a Medicare Part D prescription drug plan. Medicare Advantage plans that include Part D coverage also qualify.

BMI of 30 or higher (obesity threshold), or BMI of 27 or higher with at least one weight-related comorbidity. Qualifying conditions include type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, and osteoarthritis. For men, sleep apnea and cardiovascular disease are particularly common qualifying conditions.

Prescriber documentation. Your physician documents medical necessity. This is a clinical note, not a traditional prior authorization.

What's NOT Covered

Ozempic and Mounjaro — same active ingredients as Wegovy and Zepbound, but approved only for type 2 diabetes — are not part of the Bridge program. They continue under standard Part D diabetes coverage.

Compounded GLP-1 medications are excluded. The oral Wegovy pill was not listed among the three covered products at the time of the program announcement — check CMS.gov for updates.

Off-label use doesn't qualify. If your physician prescribes GLP-1 for heart failure or MASH without also documenting weight management, the Bridge copay won't apply.

Why This Matters for Men Over 65

Men in this age bracket have been underserved by GLP-1 access. Medicare historically excluded weight loss medications entirely from Part D. While that exclusion was lifted through recent legislation, practical copays remained prohibitively high for many retirees on fixed incomes.

The $50 copay changes the equation. A man paying $300–$500/month for compounded semaglutide or $1,000+ for brand-name Wegovy through a Part D gap can now get FDA-approved medication for $50. For men with obesity-related conditions like sleep apnea (affecting an estimated 1 in 4 men over 65), hypertension, or type 2 diabetes, the qualifying criteria are straightforward to meet.

How to Enroll

Talk to your physician about GLP-1 therapy. If you meet eligibility criteria, your prescriber submits the prescription with documentation of medical necessity. Your Part D plan processes the claim under the Bridge program, and your pharmacy copay is $50.

If your current Part D plan has implementation questions, contact them directly. CMS has indicated that all Part D plans are expected to participate, but details may vary by plan. Don't wait — schedule the conversation with your doctor now so you're ready to fill on July 1.

Bottom Line

If you're a man over 65 on Medicare with a BMI over 30 — or over 27 with high blood pressure, diabetes, sleep apnea, or heart disease — you're likely eligible for $50/month GLP-1 therapy starting July 1. This is the most affordable legitimate access to GLP-1 medications that has ever existed for this population.

Sources

• CMS Medicare GLP-1 Bridge Program FAQ, cms.gov, 2026.
• Inflation Reduction Act provisions on Medicare drug pricing and Part D coverage expansion.
• CMS program details: $50/month copay for Wegovy, Zepbound KwikPen, Foundayo.